<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>708</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15917115</PubmedId>
            <Abstract>MTB41 is a Mycobacterium antigen that is recognized by CD4+ T cells early after experimental infection of mice with Mycobacterium tuberculosis and by PBMC from healthy PPD positive individuals. Immunization of mice with plasmid DNA encoding the MTB41 gene sequence results in the development of antigen-specific CD4+ and CD8+ T cells, and protection against challenge with virulent M. tuberculosis. In the present studies, in contrast to DNA immunization, we show, that a strong MTB41-specific CD4+ T cell response, but no MHC class I restricted cytotoxic T lymphocyte (CTL) activity is detected in the spleen cells of infected mice. Therefore, this data suggests that the induction of CD8+ T cell response to MTB41 epitopes by DNA immunization may not be relevant to protection because these epitopes are not recognized during the infectious process. We also compared the repertoire of rMTB41 epitope recognition by CD4+ T cells of M. tuberculosis-infected mice with the recognition repertoire of mice immunized with the recombinant rMTB41 protein. Both regimens of sensitization lead to the recognition of the same molecular epitope. Coincidentally, immunization with the soluble recombinant protein plus adjuvant, a regimen known to generate primarily CD4+ T cells, resulted in induction of protection comparable to BCG in two well-established animal models of tuberculosis (mice and guinea pigs).</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>3937-45</ArticlePages>
            <ArticleTitle>Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Skeiky</LastName>
                    <ForeName>Yasir A W</ForeName>
                </Author>
                <Author>
                    <LastName>Alderson</LastName>
                    <ForeName>Mark R</ForeName>
                </Author>
                <Author>
                    <LastName>Ovendale</LastName>
                    <ForeName>Pamela J</ForeName>
                </Author>
                <Author>
                    <LastName>Lobet</LastName>
                    <ForeName>Yves</ForeName>
                </Author>
                <Author>
                    <LastName>Dalemans</LastName>
                    <ForeName>Wilfried</ForeName>
                </Author>
                <Author>
                    <LastName>Orme</LastName>
                    <ForeName>Ian M</ForeName>
                </Author>
                <Author>
                    <LastName>Reed</LastName>
                    <ForeName>Steven G</ForeName>
                </Author>
                <Author>
                    <LastName>Campos-Neto</LastName>
                    <ForeName>Antonio</ForeName>
                </Author>
            </Authors>
            <Affiliations>Corixa Corporation, Seattle, WA, USA.</Affiliations>
            <ArticleChemicalList>Adjuvants, Immunologic;Antigens, Bacterial;Cytokines;Epitopes;Tuberculosis Vaccines;Vaccines, Synthetic</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adjuvants, Immunologic; Amino Acid Sequence; Animals; Antigens, Bacterial(immunology); CD4-Positive T-Lymphocytes(immunology); Colony Count, Microbial; Cytokines(analysis; immunology); Epitopes(immunology); Guinea Pigs; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Mycobacterium tuberculosis(immunology); Spleen(cytology); Tuberculosis(immunology; microbiology; prevention &amp; control); Tuberculosis Vaccines(immunology); Vaccines, Synthetic(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>23</Volume>
                <Issue>30</Issue>
                <Title>Vaccine</Title>
                <Issn>0264-410X</Issn>
                <MedlineTa>Vaccine</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Peptide 1 (rMTB41 1-15)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MDFGLLPPEVNSSRM</LinearSequence>
                        <StartingPosition>1</StartingPosition>
                        <EndingPosition>15</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>41228</EpitopeId>
                <ReferenceStartingPosition>1</ReferenceStartingPosition>
                <ReferenceEndingPosition>15</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>10124</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 1 (rMTB41 1-15)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MDFGLLPPEVNSSRM</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>15</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>A positive response was obtained when lymphoid cells were analyzed from mice either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>10123</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 1 (rMTB41 1-15)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MDFGLLPPEVNSSRM</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>15</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>A positive response was obtained when lymphoid cells were analyzed from mice either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 2 (rMTB41 6-20)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LPPEVNSSRMYSGPG</LinearSequence>
                        <StartingPosition>6</StartingPosition>
                        <EndingPosition>20</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>38613</EpitopeId>
                <ReferenceStartingPosition>6</ReferenceStartingPosition>
                <ReferenceEndingPosition>20</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12129</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 2 (rMTB41 6-20)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LPPEVNSSRMYSGPG</LinearSequence>
                                        <StartingPosition>6</StartingPosition>
                                        <EndingPosition>20</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12130</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 2 (rMTB41 6-20)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LPPEVNSSRMYSGPG</LinearSequence>
                                        <StartingPosition>6</StartingPosition>
                                        <EndingPosition>20</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 3 (rMTB41 11-25)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NSSRMYSGPGPESML</LinearSequence>
                        <StartingPosition>11</StartingPosition>
                        <EndingPosition>25</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>45989</EpitopeId>
                <ReferenceStartingPosition>11</ReferenceStartingPosition>
                <ReferenceEndingPosition>25</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12132</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 3 (rMTB41 11-25)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NSSRMYSGPGPESML</LinearSequence>
                                        <StartingPosition>11</StartingPosition>
                                        <EndingPosition>25</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12131</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 3 (rMTB41 11-25)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NSSRMYSGPGPESML</LinearSequence>
                                        <StartingPosition>11</StartingPosition>
                                        <EndingPosition>25</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 4 (rMTB41 16-30)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YSGPGPESMLAAAAA</LinearSequence>
                        <StartingPosition>16</StartingPosition>
                        <EndingPosition>30</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>75749</EpitopeId>
                <ReferenceStartingPosition>16</ReferenceStartingPosition>
                <ReferenceEndingPosition>30</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12133</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 4 (rMTB41 16-30)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YSGPGPESMLAAAAA</LinearSequence>
                                        <StartingPosition>16</StartingPosition>
                                        <EndingPosition>30</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12134</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 4 (rMTB41 16-30)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YSGPGPESMLAAAAA</LinearSequence>
                                        <StartingPosition>16</StartingPosition>
                                        <EndingPosition>30</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 5 (rMTB41 21-35)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PESMLAAAAAWDGVA</LinearSequence>
                        <StartingPosition>21</StartingPosition>
                        <EndingPosition>35</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>47424</EpitopeId>
                <ReferenceStartingPosition>21</ReferenceStartingPosition>
                <ReferenceEndingPosition>35</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12136</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 5 (rMTB41 21-35)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PESMLAAAAAWDGVA</LinearSequence>
                                        <StartingPosition>21</StartingPosition>
                                        <EndingPosition>35</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12135</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 5 (rMTB41 21-35)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PESMLAAAAAWDGVA</LinearSequence>
                                        <StartingPosition>21</StartingPosition>
                                        <EndingPosition>35</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 6 (rMTB41 26-40)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AAAAAWDGVAAELTS</LinearSequence>
                        <StartingPosition>26</StartingPosition>
                        <EndingPosition>40</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>16</EpitopeId>
                <ReferenceStartingPosition>26</ReferenceStartingPosition>
                <ReferenceEndingPosition>40</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12137</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 6 (rMTB41 26-40)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAAAAWDGVAAELTS</LinearSequence>
                                        <StartingPosition>26</StartingPosition>
                                        <EndingPosition>40</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12138</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 6 (rMTB41 26-40)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAAAAWDGVAAELTS</LinearSequence>
                                        <StartingPosition>26</StartingPosition>
                                        <EndingPosition>40</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 7 (rMTB41 31-45)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>WDGVAAELTSAAVSY</LinearSequence>
                        <StartingPosition>31</StartingPosition>
                        <EndingPosition>45</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>72309</EpitopeId>
                <ReferenceStartingPosition>31</ReferenceStartingPosition>
                <ReferenceEndingPosition>45</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12139</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 7 (rMTB41 31-45)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WDGVAAELTSAAVSY</LinearSequence>
                                        <StartingPosition>31</StartingPosition>
                                        <EndingPosition>45</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12140</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 7 (rMTB41 31-45)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>WDGVAAELTSAAVSY</LinearSequence>
                                        <StartingPosition>31</StartingPosition>
                                        <EndingPosition>45</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 8 (rMTB41 36-50)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AELTSAAVSYGSVVS</LinearSequence>
                        <StartingPosition>36</StartingPosition>
                        <EndingPosition>50</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>1066</EpitopeId>
                <ReferenceStartingPosition>36</ReferenceStartingPosition>
                <ReferenceEndingPosition>50</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12141</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 8 (rMTB41 36-50)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AELTSAAVSYGSVVS</LinearSequence>
                                        <StartingPosition>36</StartingPosition>
                                        <EndingPosition>50</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12142</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 8 (rMTB41 36-50)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AELTSAAVSYGSVVS</LinearSequence>
                                        <StartingPosition>36</StartingPosition>
                                        <EndingPosition>50</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 9 (rMTB41 41-55)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AAVSYGSVVSTLIVE</LinearSequence>
                        <StartingPosition>41</StartingPosition>
                        <EndingPosition>55</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>499</EpitopeId>
                <ReferenceStartingPosition>41</ReferenceStartingPosition>
                <ReferenceEndingPosition>55</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12144</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 9 (rMTB41 41-55)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAVSYGSVVSTLIVE</LinearSequence>
                                        <StartingPosition>41</StartingPosition>
                                        <EndingPosition>55</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12143</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 9 (rMTB41 41-55)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAVSYGSVVSTLIVE</LinearSequence>
                                        <StartingPosition>41</StartingPosition>
                                        <EndingPosition>55</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 10 (rMTB41 46-60)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GSVVSTLIVEPWMGP</LinearSequence>
                        <StartingPosition>46</StartingPosition>
                        <EndingPosition>60</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>22573</EpitopeId>
                <ReferenceStartingPosition>46</ReferenceStartingPosition>
                <ReferenceEndingPosition>60</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12145</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 10 (rMTB41 46-60)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GSVVSTLIVEPWMGP</LinearSequence>
                                        <StartingPosition>46</StartingPosition>
                                        <EndingPosition>60</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12146</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 10 (rMTB41 46-60)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GSVVSTLIVEPWMGP</LinearSequence>
                                        <StartingPosition>46</StartingPosition>
                                        <EndingPosition>60</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 11 (rMTB41 51-65)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TLIVEPWMGPAAAAM</LinearSequence>
                        <StartingPosition>51</StartingPosition>
                        <EndingPosition>65</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>64865</EpitopeId>
                <ReferenceStartingPosition>51</ReferenceStartingPosition>
                <ReferenceEndingPosition>65</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12147</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 11 (rMTB41 51-65)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TLIVEPWMGPAAAAM</LinearSequence>
                                        <StartingPosition>51</StartingPosition>
                                        <EndingPosition>65</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12148</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 11 (rMTB41 51-65)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TLIVEPWMGPAAAAM</LinearSequence>
                                        <StartingPosition>51</StartingPosition>
                                        <EndingPosition>65</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 12 (rMTB41 56-70)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PWMGPAAAAMAAAAT</LinearSequence>
                        <StartingPosition>56</StartingPosition>
                        <EndingPosition>70</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>50040</EpitopeId>
                <ReferenceStartingPosition>56</ReferenceStartingPosition>
                <ReferenceEndingPosition>70</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12150</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 12 (rMTB41 56-70)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PWMGPAAAAMAAAAT</LinearSequence>
                                        <StartingPosition>56</StartingPosition>
                                        <EndingPosition>70</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12149</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 12 (rMTB41 56-70)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PWMGPAAAAMAAAAT</LinearSequence>
                                        <StartingPosition>56</StartingPosition>
                                        <EndingPosition>70</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 13 (rMTB41 61-75)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AAAAMAAAATPYVGW</LinearSequence>
                        <StartingPosition>61</StartingPosition>
                        <EndingPosition>75</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>20</EpitopeId>
                <ReferenceStartingPosition>61</ReferenceStartingPosition>
                <ReferenceEndingPosition>75</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12152</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 13 (rMTB41 61-75)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAAAMAAAATPYVGW</LinearSequence>
                                        <StartingPosition>61</StartingPosition>
                                        <EndingPosition>75</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12151</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 13 (rMTB41 61-75)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAAAMAAAATPYVGW</LinearSequence>
                                        <StartingPosition>61</StartingPosition>
                                        <EndingPosition>75</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 14 (rMTB41 66-80)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AAAATPYVGWLAATA</LinearSequence>
                        <StartingPosition>66</StartingPosition>
                        <EndingPosition>80</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>25</EpitopeId>
                <ReferenceStartingPosition>66</ReferenceStartingPosition>
                <ReferenceEndingPosition>80</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12154</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 14 (rMTB41 66-80)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAAATPYVGWLAATA</LinearSequence>
                                        <StartingPosition>66</StartingPosition>
                                        <EndingPosition>80</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12153</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 14 (rMTB41 66-80)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAAATPYVGWLAATA</LinearSequence>
                                        <StartingPosition>66</StartingPosition>
                                        <EndingPosition>80</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 15 (rMTB41 71-85)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PYVGWLAATAALAKE</LinearSequence>
                        <StartingPosition>71</StartingPosition>
                        <EndingPosition>85</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>50185</EpitopeId>
                <ReferenceStartingPosition>71</ReferenceStartingPosition>
                <ReferenceEndingPosition>85</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12156</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 15 (rMTB41 71-85)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PYVGWLAATAALAKE</LinearSequence>
                                        <StartingPosition>71</StartingPosition>
                                        <EndingPosition>85</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12155</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 15 (rMTB41 71-85)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PYVGWLAATAALAKE</LinearSequence>
                                        <StartingPosition>71</StartingPosition>
                                        <EndingPosition>85</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 16 (rMTB41 76-90)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LAATAALAKETATQA</LinearSequence>
                        <StartingPosition>76</StartingPosition>
                        <EndingPosition>90</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>34694</EpitopeId>
                <ReferenceStartingPosition>76</ReferenceStartingPosition>
                <ReferenceEndingPosition>90</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12157</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 16 (rMTB41 76-90)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LAATAALAKETATQA</LinearSequence>
                                        <StartingPosition>76</StartingPosition>
                                        <EndingPosition>90</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12158</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 16 (rMTB41 76-90)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LAATAALAKETATQA</LinearSequence>
                                        <StartingPosition>76</StartingPosition>
                                        <EndingPosition>90</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 17 (rMTB41 81-95)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ALAKETATQARAAAE</LinearSequence>
                        <StartingPosition>81</StartingPosition>
                        <EndingPosition>95</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>2422</EpitopeId>
                <ReferenceStartingPosition>81</ReferenceStartingPosition>
                <ReferenceEndingPosition>95</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12160</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 17 (rMTB41 81-95)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ALAKETATQARAAAE</LinearSequence>
                                        <StartingPosition>81</StartingPosition>
                                        <EndingPosition>95</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12159</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 17 (rMTB41 81-95)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ALAKETATQARAAAE</LinearSequence>
                                        <StartingPosition>81</StartingPosition>
                                        <EndingPosition>95</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 18 (rMTB41 86-100)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TATQARAAAEAFGTA</LinearSequence>
                        <StartingPosition>86</StartingPosition>
                        <EndingPosition>100</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>63020</EpitopeId>
                <ReferenceStartingPosition>86</ReferenceStartingPosition>
                <ReferenceEndingPosition>100</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12162</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 18 (rMTB41 86-100)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TATQARAAAEAFGTA</LinearSequence>
                                        <StartingPosition>86</StartingPosition>
                                        <EndingPosition>100</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12161</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 18 (rMTB41 86-100)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TATQARAAAEAFGTA</LinearSequence>
                                        <StartingPosition>86</StartingPosition>
                                        <EndingPosition>100</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 19 (rMTB41 91-105)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RAAAEAFGTAFAMTV</LinearSequence>
                        <StartingPosition>91</StartingPosition>
                        <EndingPosition>105</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>53054</EpitopeId>
                <ReferenceStartingPosition>91</ReferenceStartingPosition>
                <ReferenceEndingPosition>105</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12163</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 19 (rMTB41 91-105)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RAAAEAFGTAFAMTV</LinearSequence>
                                        <StartingPosition>91</StartingPosition>
                                        <EndingPosition>105</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12164</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 19 (rMTB41 91-105)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RAAAEAFGTAFAMTV</LinearSequence>
                                        <StartingPosition>91</StartingPosition>
                                        <EndingPosition>105</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 20 (rMTB41 96-110)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AFGTAFAMTVPPSLV</LinearSequence>
                        <StartingPosition>96</StartingPosition>
                        <EndingPosition>110</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>1307</EpitopeId>
                <ReferenceStartingPosition>96</ReferenceStartingPosition>
                <ReferenceEndingPosition>110</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12165</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 20 (rMTB41 96-110)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AFGTAFAMTVPPSLV</LinearSequence>
                                        <StartingPosition>96</StartingPosition>
                                        <EndingPosition>110</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12166</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 20 (rMTB41 96-110)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AFGTAFAMTVPPSLV</LinearSequence>
                                        <StartingPosition>96</StartingPosition>
                                        <EndingPosition>110</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 21 (rMTB41 101-115)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FAMTVPPSLVAANRS</LinearSequence>
                        <StartingPosition>101</StartingPosition>
                        <EndingPosition>115</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>15224</EpitopeId>
                <ReferenceStartingPosition>101</ReferenceStartingPosition>
                <ReferenceEndingPosition>115</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12167</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 21 (rMTB41 101-115)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FAMTVPPSLVAANRS</LinearSequence>
                                        <StartingPosition>101</StartingPosition>
                                        <EndingPosition>115</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12168</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 21 (rMTB41 101-115)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FAMTVPPSLVAANRS</LinearSequence>
                                        <StartingPosition>101</StartingPosition>
                                        <EndingPosition>115</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 22 (rMTB41 106-100)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PPSLVAANRSRLMSL</LinearSequence>
                        <StartingPosition>106</StartingPosition>
                        <EndingPosition>120</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>48918</EpitopeId>
                <ReferenceStartingPosition>100</ReferenceStartingPosition>
                <ReferenceEndingPosition>106</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12169</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 22 (rMTB41 106-100)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PPSLVAANRSRLMSL</LinearSequence>
                                        <StartingPosition>106</StartingPosition>
                                        <EndingPosition>120</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12170</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 22 (rMTB41 106-100)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PPSLVAANRSRLMSL</LinearSequence>
                                        <StartingPosition>106</StartingPosition>
                                        <EndingPosition>120</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 23 (rMTB41 111-125)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AANRSRLMSLVAANI</LinearSequence>
                        <StartingPosition>111</StartingPosition>
                        <EndingPosition>125</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>339</EpitopeId>
                <ReferenceStartingPosition>111</ReferenceStartingPosition>
                <ReferenceEndingPosition>125</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12171</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 23 (rMTB41 111-125)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AANRSRLMSLVAANI</LinearSequence>
                                        <StartingPosition>111</StartingPosition>
                                        <EndingPosition>125</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12172</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 23 (rMTB41 111-125)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AANRSRLMSLVAANI</LinearSequence>
                                        <StartingPosition>111</StartingPosition>
                                        <EndingPosition>125</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 24 (rMTB41 116-130)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RLMSLVAANILGQNS</LinearSequence>
                        <StartingPosition>116</StartingPosition>
                        <EndingPosition>130</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>54675</EpitopeId>
                <ReferenceStartingPosition>116</ReferenceStartingPosition>
                <ReferenceEndingPosition>130</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12174</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 24 (rMTB41 116-130)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RLMSLVAANILGQNS</LinearSequence>
                                        <StartingPosition>116</StartingPosition>
                                        <EndingPosition>130</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12173</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 24 (rMTB41 116-130)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RLMSLVAANILGQNS</LinearSequence>
                                        <StartingPosition>116</StartingPosition>
                                        <EndingPosition>130</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 25 (rMTB41 121-135)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VAANILGQNSAAIAA</LinearSequence>
                        <StartingPosition>121</StartingPosition>
                        <EndingPosition>135</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>67528</EpitopeId>
                <ReferenceStartingPosition>121</ReferenceStartingPosition>
                <ReferenceEndingPosition>135</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12175</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 25 (rMTB41 121-135)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VAANILGQNSAAIAA</LinearSequence>
                                        <StartingPosition>121</StartingPosition>
                                        <EndingPosition>135</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12176</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 25 (rMTB41 121-135)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VAANILGQNSAAIAA</LinearSequence>
                                        <StartingPosition>121</StartingPosition>
                                        <EndingPosition>135</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 26 (rMTB41 126-140)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LGQNSAAIAATQAEY</LinearSequence>
                        <StartingPosition>126</StartingPosition>
                        <EndingPosition>140</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>36281</EpitopeId>
                <ReferenceStartingPosition>126</ReferenceStartingPosition>
                <ReferenceEndingPosition>140</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12177</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 26 (rMTB41 126-140)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LGQNSAAIAATQAEY</LinearSequence>
                                        <StartingPosition>126</StartingPosition>
                                        <EndingPosition>140</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12178</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 26 (rMTB41 126-140)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LGQNSAAIAATQAEY</LinearSequence>
                                        <StartingPosition>126</StartingPosition>
                                        <EndingPosition>140</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 27 (rMTB41 131-145)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AAIAATQAEYAEMWA</LinearSequence>
                        <StartingPosition>131</StartingPosition>
                        <EndingPosition>145</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>203</EpitopeId>
                <ReferenceStartingPosition>131</ReferenceStartingPosition>
                <ReferenceEndingPosition>145</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12180</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 27 (rMTB41 131-145)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAIAATQAEYAEMWA</LinearSequence>
                                        <StartingPosition>131</StartingPosition>
                                        <EndingPosition>145</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12179</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 27 (rMTB41 131-145)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAIAATQAEYAEMWA</LinearSequence>
                                        <StartingPosition>131</StartingPosition>
                                        <EndingPosition>145</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 28 (rMTB41 136-150)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TQAEYAEMWAQDAAV</LinearSequence>
                        <StartingPosition>136</StartingPosition>
                        <EndingPosition>150</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>65818</EpitopeId>
                <ReferenceStartingPosition>136</ReferenceStartingPosition>
                <ReferenceEndingPosition>150</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12181</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 28 (rMTB41 136-150)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TQAEYAEMWAQDAAV</LinearSequence>
                                        <StartingPosition>136</StartingPosition>
                                        <EndingPosition>150</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12182</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 28 (rMTB41 136-150)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TQAEYAEMWAQDAAV</LinearSequence>
                                        <StartingPosition>136</StartingPosition>
                                        <EndingPosition>150</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 29 (rMTB41 141-155)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AEMWAQDAAVMYSYE</LinearSequence>
                        <StartingPosition>141</StartingPosition>
                        <EndingPosition>155</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>1089</EpitopeId>
                <ReferenceStartingPosition>141</ReferenceStartingPosition>
                <ReferenceEndingPosition>155</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12183</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 29 (rMTB41 141-155)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AEMWAQDAAVMYSYE</LinearSequence>
                                        <StartingPosition>141</StartingPosition>
                                        <EndingPosition>155</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12184</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 29 (rMTB41 141-155)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AEMWAQDAAVMYSYE</LinearSequence>
                                        <StartingPosition>141</StartingPosition>
                                        <EndingPosition>155</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 30 (rMTB41 146-160)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>QDAAVMYSYEGASAA</LinearSequence>
                        <StartingPosition>146</StartingPosition>
                        <EndingPosition>160</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>50428</EpitopeId>
                <ReferenceStartingPosition>146</ReferenceStartingPosition>
                <ReferenceEndingPosition>160</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12186</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 30 (rMTB41 146-160)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QDAAVMYSYEGASAA</LinearSequence>
                                        <StartingPosition>146</StartingPosition>
                                        <EndingPosition>160</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12185</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 30 (rMTB41 146-160)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QDAAVMYSYEGASAA</LinearSequence>
                                        <StartingPosition>146</StartingPosition>
                                        <EndingPosition>160</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 31 (rMTB41 151-165)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MYSYEGASAAASALP</LinearSequence>
                        <StartingPosition>151</StartingPosition>
                        <EndingPosition>165</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>43090</EpitopeId>
                <ReferenceStartingPosition>151</ReferenceStartingPosition>
                <ReferenceEndingPosition>165</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12188</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 31 (rMTB41 151-165)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MYSYEGASAAASALP</LinearSequence>
                                        <StartingPosition>151</StartingPosition>
                                        <EndingPosition>165</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12187</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 31 (rMTB41 151-165)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MYSYEGASAAASALP</LinearSequence>
                                        <StartingPosition>151</StartingPosition>
                                        <EndingPosition>165</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 32 (rMTB41 156-170)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GASAAASALPPFTPP</LinearSequence>
                        <StartingPosition>156</StartingPosition>
                        <EndingPosition>170</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>18756</EpitopeId>
                <ReferenceStartingPosition>156</ReferenceStartingPosition>
                <ReferenceEndingPosition>170</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12189</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 32 (rMTB41 156-170)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GASAAASALPPFTPP</LinearSequence>
                                        <StartingPosition>156</StartingPosition>
                                        <EndingPosition>170</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12190</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 32 (rMTB41 156-170)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GASAAASALPPFTPP</LinearSequence>
                                        <StartingPosition>156</StartingPosition>
                                        <EndingPosition>170</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 33 (rMTB41 161-175)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ASALPPFTPPVQGTG</LinearSequence>
                        <StartingPosition>161</StartingPosition>
                        <EndingPosition>175</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>4319</EpitopeId>
                <ReferenceStartingPosition>161</ReferenceStartingPosition>
                <ReferenceEndingPosition>175</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12192</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 33 (rMTB41 161-175)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASALPPFTPPVQGTG</LinearSequence>
                                        <StartingPosition>161</StartingPosition>
                                        <EndingPosition>175</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12191</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 33 (rMTB41 161-175)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASALPPFTPPVQGTG</LinearSequence>
                                        <StartingPosition>161</StartingPosition>
                                        <EndingPosition>175</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 34 (rMTB41 166-180)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PFTPPVQGTGPAGPA</LinearSequence>
                        <StartingPosition>166</StartingPosition>
                        <EndingPosition>180</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>47577</EpitopeId>
                <ReferenceStartingPosition>166</ReferenceStartingPosition>
                <ReferenceEndingPosition>180</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12193</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 34 (rMTB41 166-180)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PFTPPVQGTGPAGPA</LinearSequence>
                                        <StartingPosition>166</StartingPosition>
                                        <EndingPosition>180</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12194</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 34 (rMTB41 166-180)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PFTPPVQGTGPAGPA</LinearSequence>
                                        <StartingPosition>166</StartingPosition>
                                        <EndingPosition>180</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 35 (rMTB41 171-185)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VQGTGPAGPAAAAAA</LinearSequence>
                        <StartingPosition>171</StartingPosition>
                        <EndingPosition>185</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>70565</EpitopeId>
                <ReferenceStartingPosition>171</ReferenceStartingPosition>
                <ReferenceEndingPosition>185</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12195</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 35 (rMTB41 171-185)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VQGTGPAGPAAAAAA</LinearSequence>
                                        <StartingPosition>171</StartingPosition>
                                        <EndingPosition>185</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12196</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 35 (rMTB41 171-185)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VQGTGPAGPAAAAAA</LinearSequence>
                                        <StartingPosition>171</StartingPosition>
                                        <EndingPosition>185</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 36 (rMTB41 176-190)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PAGPAAAAAATQAAG</LinearSequence>
                        <StartingPosition>176</StartingPosition>
                        <EndingPosition>190</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>46807</EpitopeId>
                <ReferenceStartingPosition>176</ReferenceStartingPosition>
                <ReferenceEndingPosition>190</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12198</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 36 (rMTB41 176-190)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PAGPAAAAAATQAAG</LinearSequence>
                                        <StartingPosition>176</StartingPosition>
                                        <EndingPosition>190</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12197</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 36 (rMTB41 176-190)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PAGPAAAAAATQAAG</LinearSequence>
                                        <StartingPosition>176</StartingPosition>
                                        <EndingPosition>190</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 37 (rMTB41 181-195)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AAAAATQAAGAGAVA</LinearSequence>
                        <StartingPosition>181</StartingPosition>
                        <EndingPosition>195</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>13</EpitopeId>
                <ReferenceStartingPosition>181</ReferenceStartingPosition>
                <ReferenceEndingPosition>195</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12200</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 37 (rMTB41 181-195)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAAAATQAAGAGAVA</LinearSequence>
                                        <StartingPosition>181</StartingPosition>
                                        <EndingPosition>195</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12199</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 37 (rMTB41 181-195)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAAAATQAAGAGAVA</LinearSequence>
                                        <StartingPosition>181</StartingPosition>
                                        <EndingPosition>195</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 38 (rMTB41 186-200)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TQAAGAGAVADAQAT</LinearSequence>
                        <StartingPosition>186</StartingPosition>
                        <EndingPosition>200</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>65815</EpitopeId>
                <ReferenceStartingPosition>186</ReferenceStartingPosition>
                <ReferenceEndingPosition>200</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12201</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 38 (rMTB41 186-200)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TQAAGAGAVADAQAT</LinearSequence>
                                        <StartingPosition>186</StartingPosition>
                                        <EndingPosition>200</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12202</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 38 (rMTB41 186-200)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TQAAGAGAVADAQAT</LinearSequence>
                                        <StartingPosition>186</StartingPosition>
                                        <EndingPosition>200</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 39 (rMTB41 191-205)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AGAVADAQATLAQLP</LinearSequence>
                        <StartingPosition>191</StartingPosition>
                        <EndingPosition>205</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>1456</EpitopeId>
                <ReferenceStartingPosition>191</ReferenceStartingPosition>
                <ReferenceEndingPosition>205</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12203</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 39 (rMTB41 191-205)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AGAVADAQATLAQLP</LinearSequence>
                                        <StartingPosition>191</StartingPosition>
                                        <EndingPosition>205</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12204</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 39 (rMTB41 191-205)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AGAVADAQATLAQLP</LinearSequence>
                                        <StartingPosition>191</StartingPosition>
                                        <EndingPosition>205</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 40 (rMTB41 196-210)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DAQATLAQLPPGILS</LinearSequence>
                        <StartingPosition>196</StartingPosition>
                        <EndingPosition>210</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>7619</EpitopeId>
                <ReferenceStartingPosition>196</ReferenceStartingPosition>
                <ReferenceEndingPosition>210</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12206</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 40 (rMTB41 196-210)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DAQATLAQLPPGILS</LinearSequence>
                                        <StartingPosition>196</StartingPosition>
                                        <EndingPosition>210</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12205</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 40 (rMTB41 196-210)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DAQATLAQLPPGILS</LinearSequence>
                                        <StartingPosition>196</StartingPosition>
                                        <EndingPosition>210</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 41 (rMTB41 201-215)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LAQLPPGILSDILSA</LinearSequence>
                        <StartingPosition>201</StartingPosition>
                        <EndingPosition>215</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>34934</EpitopeId>
                <ReferenceStartingPosition>201</ReferenceStartingPosition>
                <ReferenceEndingPosition>215</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12208</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 41 (rMTB41 201-215)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LAQLPPGILSDILSA</LinearSequence>
                                        <StartingPosition>201</StartingPosition>
                                        <EndingPosition>215</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12207</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 41 (rMTB41 201-215)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LAQLPPGILSDILSA</LinearSequence>
                                        <StartingPosition>201</StartingPosition>
                                        <EndingPosition>215</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 42 (rMTB41 206-220)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PGILSDILSALAANA</LinearSequence>
                        <StartingPosition>206</StartingPosition>
                        <EndingPosition>220</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>47680</EpitopeId>
                <ReferenceStartingPosition>206</ReferenceStartingPosition>
                <ReferenceEndingPosition>220</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12209</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 42 (rMTB41 206-220)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PGILSDILSALAANA</LinearSequence>
                                        <StartingPosition>206</StartingPosition>
                                        <EndingPosition>220</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12210</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 42 (rMTB41 206-220)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PGILSDILSALAANA</LinearSequence>
                                        <StartingPosition>206</StartingPosition>
                                        <EndingPosition>220</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 43 (rMTB41 211-225)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DILSALAANADPLTS</LinearSequence>
                        <StartingPosition>211</StartingPosition>
                        <EndingPosition>225</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>8713</EpitopeId>
                <ReferenceStartingPosition>211</ReferenceStartingPosition>
                <ReferenceEndingPosition>225</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12211</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 43 (rMTB41 211-225)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DILSALAANADPLTS</LinearSequence>
                                        <StartingPosition>211</StartingPosition>
                                        <EndingPosition>225</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12212</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 43 (rMTB41 211-225)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DILSALAANADPLTS</LinearSequence>
                                        <StartingPosition>211</StartingPosition>
                                        <EndingPosition>225</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 44 (rMTB41 216-230)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LAANADPLTSGLLGI</LinearSequence>
                        <StartingPosition>216</StartingPosition>
                        <EndingPosition>230</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>34683</EpitopeId>
                <ReferenceStartingPosition>216</ReferenceStartingPosition>
                <ReferenceEndingPosition>230</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12214</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 44 (rMTB41 216-230)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LAANADPLTSGLLGI</LinearSequence>
                                        <StartingPosition>216</StartingPosition>
                                        <EndingPosition>230</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12213</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 44 (rMTB41 216-230)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LAANADPLTSGLLGI</LinearSequence>
                                        <StartingPosition>216</StartingPosition>
                                        <EndingPosition>230</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 45 (rMTB41 221-235)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DPLTSGLLGIASTLN</LinearSequence>
                        <StartingPosition>221</StartingPosition>
                        <EndingPosition>235</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>9676</EpitopeId>
                <ReferenceStartingPosition>221</ReferenceStartingPosition>
                <ReferenceEndingPosition>235</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12216</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 45 (rMTB41 221-235)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DPLTSGLLGIASTLN</LinearSequence>
                                        <StartingPosition>221</StartingPosition>
                                        <EndingPosition>235</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12215</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 45 (rMTB41 221-235)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DPLTSGLLGIASTLN</LinearSequence>
                                        <StartingPosition>221</StartingPosition>
                                        <EndingPosition>235</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 46 (rMTB41 226-240)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GLLGIASTLNPQVGS</LinearSequence>
                        <StartingPosition>226</StartingPosition>
                        <EndingPosition>240</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>20993</EpitopeId>
                <ReferenceStartingPosition>226</ReferenceStartingPosition>
                <ReferenceEndingPosition>240</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12217</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 46 (rMTB41 226-240)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GLLGIASTLNPQVGS</LinearSequence>
                                        <StartingPosition>226</StartingPosition>
                                        <EndingPosition>240</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12218</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 46 (rMTB41 226-240)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GLLGIASTLNPQVGS</LinearSequence>
                                        <StartingPosition>226</StartingPosition>
                                        <EndingPosition>240</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 47 (rMTB41 231-245)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ASTLNPQVGSAQPIV</LinearSequence>
                        <StartingPosition>231</StartingPosition>
                        <EndingPosition>245</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>4800</EpitopeId>
                <ReferenceStartingPosition>231</ReferenceStartingPosition>
                <ReferenceEndingPosition>245</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12219</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 47 (rMTB41 231-245)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASTLNPQVGSAQPIV</LinearSequence>
                                        <StartingPosition>231</StartingPosition>
                                        <EndingPosition>245</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12220</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 47 (rMTB41 231-245)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASTLNPQVGSAQPIV</LinearSequence>
                                        <StartingPosition>231</StartingPosition>
                                        <EndingPosition>245</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 48 (rMTB41 236-250)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PQVGSAQPIVIPTPI</LinearSequence>
                        <StartingPosition>236</StartingPosition>
                        <EndingPosition>250</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>49144</EpitopeId>
                <ReferenceStartingPosition>236</ReferenceStartingPosition>
                <ReferenceEndingPosition>250</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12222</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 48 (rMTB41 236-250)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PQVGSAQPIVIPTPI</LinearSequence>
                                        <StartingPosition>236</StartingPosition>
                                        <EndingPosition>250</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12221</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 48 (rMTB41 236-250)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PQVGSAQPIVIPTPI</LinearSequence>
                                        <StartingPosition>236</StartingPosition>
                                        <EndingPosition>250</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 49 (rMTB41 241-255)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AQPIVIPTPIGELDV</LinearSequence>
                        <StartingPosition>241</StartingPosition>
                        <EndingPosition>255</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>4030</EpitopeId>
                <ReferenceStartingPosition>241</ReferenceStartingPosition>
                <ReferenceEndingPosition>255</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12224</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 49 (rMTB41 241-255)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AQPIVIPTPIGELDV</LinearSequence>
                                        <StartingPosition>241</StartingPosition>
                                        <EndingPosition>255</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12223</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 49 (rMTB41 241-255)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AQPIVIPTPIGELDV</LinearSequence>
                                        <StartingPosition>241</StartingPosition>
                                        <EndingPosition>255</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 50 (rMTB41 246-260)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>IPTPIGELDVIALYI</LinearSequence>
                        <StartingPosition>246</StartingPosition>
                        <EndingPosition>260</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>28092</EpitopeId>
                <ReferenceStartingPosition>246</ReferenceStartingPosition>
                <ReferenceEndingPosition>260</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12226</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 50 (rMTB41 246-260)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IPTPIGELDVIALYI</LinearSequence>
                                        <StartingPosition>246</StartingPosition>
                                        <EndingPosition>260</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12225</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 50 (rMTB41 246-260)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IPTPIGELDVIALYI</LinearSequence>
                                        <StartingPosition>246</StartingPosition>
                                        <EndingPosition>260</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 51 (rMTB41 251-265)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GELDVIALYIASIAT</LinearSequence>
                        <StartingPosition>251</StartingPosition>
                        <EndingPosition>265</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>19340</EpitopeId>
                <ReferenceStartingPosition>251</ReferenceStartingPosition>
                <ReferenceEndingPosition>265</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12228</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 51 (rMTB41 251-265)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GELDVIALYIASIAT</LinearSequence>
                                        <StartingPosition>251</StartingPosition>
                                        <EndingPosition>265</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12227</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 51 (rMTB41 251-265)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GELDVIALYIASIAT</LinearSequence>
                                        <StartingPosition>251</StartingPosition>
                                        <EndingPosition>265</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 52 (rMTB41 256-270)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>IALYIASIATGSIAL</LinearSequence>
                        <StartingPosition>256</StartingPosition>
                        <EndingPosition>270</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>25350</EpitopeId>
                <ReferenceStartingPosition>256</ReferenceStartingPosition>
                <ReferenceEndingPosition>270</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12229</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 52 (rMTB41 256-270)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IALYIASIATGSIAL</LinearSequence>
                                        <StartingPosition>256</StartingPosition>
                                        <EndingPosition>270</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12230</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 52 (rMTB41 256-270)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IALYIASIATGSIAL</LinearSequence>
                                        <StartingPosition>256</StartingPosition>
                                        <EndingPosition>270</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 53 (rMTB41 261-275)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ASIATGSIALAITNT</LinearSequence>
                        <StartingPosition>261</StartingPosition>
                        <EndingPosition>275</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>4465</EpitopeId>
                <ReferenceStartingPosition>261</ReferenceStartingPosition>
                <ReferenceEndingPosition>275</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12231</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 53 (rMTB41 261-275)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASIATGSIALAITNT</LinearSequence>
                                        <StartingPosition>261</StartingPosition>
                                        <EndingPosition>275</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12232</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 53 (rMTB41 261-275)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASIATGSIALAITNT</LinearSequence>
                                        <StartingPosition>261</StartingPosition>
                                        <EndingPosition>275</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 54 (rMTB41 266-280)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GSIALAITNTARPWH</LinearSequence>
                        <StartingPosition>266</StartingPosition>
                        <EndingPosition>280</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>22369</EpitopeId>
                <ReferenceStartingPosition>266</ReferenceStartingPosition>
                <ReferenceEndingPosition>280</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12233</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 54 (rMTB41 266-280)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GSIALAITNTARPWH</LinearSequence>
                                        <StartingPosition>266</StartingPosition>
                                        <EndingPosition>280</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12234</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 54 (rMTB41 266-280)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GSIALAITNTARPWH</LinearSequence>
                                        <StartingPosition>266</StartingPosition>
                                        <EndingPosition>280</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 55 (rMTB41 271-285)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AITNTARPWHIGLYG</LinearSequence>
                        <StartingPosition>271</StartingPosition>
                        <EndingPosition>285</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>2109</EpitopeId>
                <ReferenceStartingPosition>271</ReferenceStartingPosition>
                <ReferenceEndingPosition>285</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12235</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 55 (rMTB41 271-285)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AITNTARPWHIGLYG</LinearSequence>
                                        <StartingPosition>271</StartingPosition>
                                        <EndingPosition>285</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12236</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 55 (rMTB41 271-285)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AITNTARPWHIGLYG</LinearSequence>
                                        <StartingPosition>271</StartingPosition>
                                        <EndingPosition>285</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 56 (rMTB41 276-290)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ARPWHIGLYGNAGGL</LinearSequence>
                        <StartingPosition>276</StartingPosition>
                        <EndingPosition>290</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>4216</EpitopeId>
                <ReferenceStartingPosition>276</ReferenceStartingPosition>
                <ReferenceEndingPosition>290</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12238</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 56 (rMTB41 276-290)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ARPWHIGLYGNAGGL</LinearSequence>
                                        <StartingPosition>276</StartingPosition>
                                        <EndingPosition>290</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12237</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 56 (rMTB41 276-290)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ARPWHIGLYGNAGGL</LinearSequence>
                                        <StartingPosition>276</StartingPosition>
                                        <EndingPosition>290</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 57 (rMTB41 281-295)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>IGLYGNAGGLGPTQG</LinearSequence>
                        <StartingPosition>281</StartingPosition>
                        <EndingPosition>295</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>26272</EpitopeId>
                <ReferenceStartingPosition>281</ReferenceStartingPosition>
                <ReferenceEndingPosition>295</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12240</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 57 (rMTB41 281-295)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IGLYGNAGGLGPTQG</LinearSequence>
                                        <StartingPosition>281</StartingPosition>
                                        <EndingPosition>295</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12239</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 57 (rMTB41 281-295)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>IGLYGNAGGLGPTQG</LinearSequence>
                                        <StartingPosition>281</StartingPosition>
                                        <EndingPosition>295</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 58 (rMTB41 286-300)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NAGGLGPTQGHPLSS</LinearSequence>
                        <StartingPosition>286</StartingPosition>
                        <EndingPosition>300</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>43151</EpitopeId>
                <ReferenceStartingPosition>286</ReferenceStartingPosition>
                <ReferenceEndingPosition>300</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12241</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 58 (rMTB41 286-300)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NAGGLGPTQGHPLSS</LinearSequence>
                                        <StartingPosition>286</StartingPosition>
                                        <EndingPosition>300</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12242</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 58 (rMTB41 286-300)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NAGGLGPTQGHPLSS</LinearSequence>
                                        <StartingPosition>286</StartingPosition>
                                        <EndingPosition>300</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 59 (rMTB41 291-305)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GPTQGHPLSSATDEP</LinearSequence>
                        <StartingPosition>291</StartingPosition>
                        <EndingPosition>305</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>21811</EpitopeId>
                <ReferenceStartingPosition>291</ReferenceStartingPosition>
                <ReferenceEndingPosition>305</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12244</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 59 (rMTB41 291-305)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GPTQGHPLSSATDEP</LinearSequence>
                                        <StartingPosition>291</StartingPosition>
                                        <EndingPosition>305</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12243</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 59 (rMTB41 291-305)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GPTQGHPLSSATDEP</LinearSequence>
                                        <StartingPosition>291</StartingPosition>
                                        <EndingPosition>305</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 60 (rMTB41 296-310)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>HPLSSATDEPEPHWG</LinearSequence>
                        <StartingPosition>296</StartingPosition>
                        <EndingPosition>310</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>24474</EpitopeId>
                <ReferenceStartingPosition>296</ReferenceStartingPosition>
                <ReferenceEndingPosition>310</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12245</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 60 (rMTB41 296-310)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HPLSSATDEPEPHWG</LinearSequence>
                                        <StartingPosition>296</StartingPosition>
                                        <EndingPosition>310</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12246</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 60 (rMTB41 296-310)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HPLSSATDEPEPHWG</LinearSequence>
                                        <StartingPosition>296</StartingPosition>
                                        <EndingPosition>310</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 61 (rMTB41 301-315)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ATDEPEPHWGPFGGA</LinearSequence>
                        <StartingPosition>301</StartingPosition>
                        <EndingPosition>315</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>4918</EpitopeId>
                <ReferenceStartingPosition>301</ReferenceStartingPosition>
                <ReferenceEndingPosition>315</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12248</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 61 (rMTB41 301-315)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ATDEPEPHWGPFGGA</LinearSequence>
                                        <StartingPosition>301</StartingPosition>
                                        <EndingPosition>315</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12247</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 61 (rMTB41 301-315)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ATDEPEPHWGPFGGA</LinearSequence>
                                        <StartingPosition>301</StartingPosition>
                                        <EndingPosition>315</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 62 (rMTB41 306-320)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>EPHWGPFGGAAPVSA</LinearSequence>
                        <StartingPosition>306</StartingPosition>
                        <EndingPosition>320</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>13660</EpitopeId>
                <ReferenceStartingPosition>306</ReferenceStartingPosition>
                <ReferenceEndingPosition>320</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12249</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 62 (rMTB41 306-320)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EPHWGPFGGAAPVSA</LinearSequence>
                                        <StartingPosition>306</StartingPosition>
                                        <EndingPosition>320</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12250</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 62 (rMTB41 306-320)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EPHWGPFGGAAPVSA</LinearSequence>
                                        <StartingPosition>306</StartingPosition>
                                        <EndingPosition>320</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 63 (rMTB41 311-325)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>PFGGAAPVSAGVGHA</LinearSequence>
                        <StartingPosition>311</StartingPosition>
                        <EndingPosition>325</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>47497</EpitopeId>
                <ReferenceStartingPosition>311</ReferenceStartingPosition>
                <ReferenceEndingPosition>325</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12252</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 63 (rMTB41 311-325)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PFGGAAPVSAGVGHA</LinearSequence>
                                        <StartingPosition>311</StartingPosition>
                                        <EndingPosition>325</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12251</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 63 (rMTB41 311-325)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>PFGGAAPVSAGVGHA</LinearSequence>
                                        <StartingPosition>311</StartingPosition>
                                        <EndingPosition>325</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 64 (rMTB41 316-330)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>APVSAGVGHAALVGA</LinearSequence>
                        <StartingPosition>316</StartingPosition>
                        <EndingPosition>330</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>3895</EpitopeId>
                <ReferenceStartingPosition>316</ReferenceStartingPosition>
                <ReferenceEndingPosition>330</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12254</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 64 (rMTB41 316-330)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>APVSAGVGHAALVGA</LinearSequence>
                                        <StartingPosition>316</StartingPosition>
                                        <EndingPosition>330</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12253</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 64 (rMTB41 316-330)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>APVSAGVGHAALVGA</LinearSequence>
                                        <StartingPosition>316</StartingPosition>
                                        <EndingPosition>330</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 65 (rMTB41 321-335)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GVGHAALVGALSVPH</LinearSequence>
                        <StartingPosition>321</StartingPosition>
                        <EndingPosition>335</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>22979</EpitopeId>
                <ReferenceStartingPosition>321</ReferenceStartingPosition>
                <ReferenceEndingPosition>335</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12255</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 65 (rMTB41 321-335)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GVGHAALVGALSVPH</LinearSequence>
                                        <StartingPosition>321</StartingPosition>
                                        <EndingPosition>335</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12256</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 65 (rMTB41 321-335)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GVGHAALVGALSVPH</LinearSequence>
                                        <StartingPosition>321</StartingPosition>
                                        <EndingPosition>335</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 66 (rMTB41 326-340)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ALVGALSVPHSWTTA</LinearSequence>
                        <StartingPosition>326</StartingPosition>
                        <EndingPosition>340</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>2960</EpitopeId>
                <ReferenceStartingPosition>326</ReferenceStartingPosition>
                <ReferenceEndingPosition>340</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12257</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 66 (rMTB41 326-340)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ALVGALSVPHSWTTA</LinearSequence>
                                        <StartingPosition>326</StartingPosition>
                                        <EndingPosition>340</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12258</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 66 (rMTB41 326-340)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ALVGALSVPHSWTTA</LinearSequence>
                                        <StartingPosition>326</StartingPosition>
                                        <EndingPosition>340</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 67 (rMTB41 331-345)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LSVPHSWTTAAPEIQ</LinearSequence>
                        <StartingPosition>331</StartingPosition>
                        <EndingPosition>345</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>39744</EpitopeId>
                <ReferenceStartingPosition>331</ReferenceStartingPosition>
                <ReferenceEndingPosition>345</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12259</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 67 (rMTB41 331-345)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LSVPHSWTTAAPEIQ</LinearSequence>
                                        <StartingPosition>331</StartingPosition>
                                        <EndingPosition>345</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12260</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 67 (rMTB41 331-345)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LSVPHSWTTAAPEIQ</LinearSequence>
                                        <StartingPosition>331</StartingPosition>
                                        <EndingPosition>345</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 68 (rMTB41 336-350)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SWTTAAPEIQLAVQA</LinearSequence>
                        <StartingPosition>336</StartingPosition>
                        <EndingPosition>350</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>62499</EpitopeId>
                <ReferenceStartingPosition>336</ReferenceStartingPosition>
                <ReferenceEndingPosition>350</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12261</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 68 (rMTB41 336-350)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SWTTAAPEIQLAVQA</LinearSequence>
                                        <StartingPosition>336</StartingPosition>
                                        <EndingPosition>350</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12262</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 68 (rMTB41 336-350)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SWTTAAPEIQLAVQA</LinearSequence>
                                        <StartingPosition>336</StartingPosition>
                                        <EndingPosition>350</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 69 (rMTB41 341-355)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>APEIQLAVQATPTFS</LinearSequence>
                        <StartingPosition>341</StartingPosition>
                        <EndingPosition>355</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>3533</EpitopeId>
                <ReferenceStartingPosition>341</ReferenceStartingPosition>
                <ReferenceEndingPosition>355</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12264</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 69 (rMTB41 341-355)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>APEIQLAVQATPTFS</LinearSequence>
                                        <StartingPosition>341</StartingPosition>
                                        <EndingPosition>355</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12263</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 69 (rMTB41 341-355)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>APEIQLAVQATPTFS</LinearSequence>
                                        <StartingPosition>341</StartingPosition>
                                        <EndingPosition>355</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 70 (rMTB41 346-360)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LAVQATPTFSSSAGA</LinearSequence>
                        <StartingPosition>346</StartingPosition>
                        <EndingPosition>360</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>35013</EpitopeId>
                <ReferenceStartingPosition>346</ReferenceStartingPosition>
                <ReferenceEndingPosition>360</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12265</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 70 (rMTB41 346-360)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LAVQATPTFSSSAGA</LinearSequence>
                                        <StartingPosition>346</StartingPosition>
                                        <EndingPosition>360</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12266</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 70 (rMTB41 346-360)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LAVQATPTFSSSAGA</LinearSequence>
                                        <StartingPosition>346</StartingPosition>
                                        <EndingPosition>360</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 71 (rMTB41 351-365)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TPTFSSSAGADPTAL</LinearSequence>
                        <StartingPosition>351</StartingPosition>
                        <EndingPosition>365</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>65783</EpitopeId>
                <ReferenceStartingPosition>351</ReferenceStartingPosition>
                <ReferenceEndingPosition>365</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12267</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 71 (rMTB41 351-365)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TPTFSSSAGADPTAL</LinearSequence>
                                        <StartingPosition>351</StartingPosition>
                                        <EndingPosition>365</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12268</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 71 (rMTB41 351-365)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TPTFSSSAGADPTAL</LinearSequence>
                                        <StartingPosition>351</StartingPosition>
                                        <EndingPosition>365</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 72 (rMTB41 356-370)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SSAGADPTALNGMPA</LinearSequence>
                        <StartingPosition>356</StartingPosition>
                        <EndingPosition>370</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>60884</EpitopeId>
                <ReferenceStartingPosition>356</ReferenceStartingPosition>
                <ReferenceEndingPosition>370</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12270</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 72 (rMTB41 356-370)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SSAGADPTALNGMPA</LinearSequence>
                                        <StartingPosition>356</StartingPosition>
                                        <EndingPosition>370</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12269</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 72 (rMTB41 356-370)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SSAGADPTALNGMPA</LinearSequence>
                                        <StartingPosition>356</StartingPosition>
                                        <EndingPosition>370</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 73 (rMTB41 361-375)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DPTALNGMPAGLLSG</LinearSequence>
                        <StartingPosition>361</StartingPosition>
                        <EndingPosition>375</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>9773</EpitopeId>
                <ReferenceStartingPosition>361</ReferenceStartingPosition>
                <ReferenceEndingPosition>375</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12272</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 73 (rMTB41 361-375)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DPTALNGMPAGLLSG</LinearSequence>
                                        <StartingPosition>361</StartingPosition>
                                        <EndingPosition>375</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12271</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 73 (rMTB41 361-375)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DPTALNGMPAGLLSG</LinearSequence>
                                        <StartingPosition>361</StartingPosition>
                                        <EndingPosition>375</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 74 (rMTB41 366-380)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NGMPAGLLSGMALAS</LinearSequence>
                        <StartingPosition>366</StartingPosition>
                        <EndingPosition>380</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>44032</EpitopeId>
                <ReferenceStartingPosition>366</ReferenceStartingPosition>
                <ReferenceEndingPosition>380</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12274</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 74 (rMTB41 366-380)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NGMPAGLLSGMALAS</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>380</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12273</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 74 (rMTB41 366-380)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NGMPAGLLSGMALAS</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>380</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 75 (rMTB41 371-385)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GLLSGMALASLAARG</LinearSequence>
                        <StartingPosition>371</StartingPosition>
                        <EndingPosition>385</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>21029</EpitopeId>
                <ReferenceStartingPosition>371</ReferenceStartingPosition>
                <ReferenceEndingPosition>385</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12275</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 75 (rMTB41 371-385)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GLLSGMALASLAARG</LinearSequence>
                                        <StartingPosition>371</StartingPosition>
                                        <EndingPosition>385</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12276</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 75 (rMTB41 371-385)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GLLSGMALASLAARG</LinearSequence>
                                        <StartingPosition>371</StartingPosition>
                                        <EndingPosition>385</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 76 (rMTB41 376-390)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MALASLAARGTTGGG</LinearSequence>
                        <StartingPosition>376</StartingPosition>
                        <EndingPosition>390</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>41074</EpitopeId>
                <ReferenceStartingPosition>376</ReferenceStartingPosition>
                <ReferenceEndingPosition>390</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12278</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 76 (rMTB41 376-390)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MALASLAARGTTGGG</LinearSequence>
                                        <StartingPosition>376</StartingPosition>
                                        <EndingPosition>390</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12277</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 76 (rMTB41 376-390)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MALASLAARGTTGGG</LinearSequence>
                                        <StartingPosition>376</StartingPosition>
                                        <EndingPosition>390</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 77 (rMTB41 381-395)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LAARGTTGGGGTRSG</LinearSequence>
                        <StartingPosition>381</StartingPosition>
                        <EndingPosition>395</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>34687</EpitopeId>
                <ReferenceStartingPosition>381</ReferenceStartingPosition>
                <ReferenceEndingPosition>395</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12279</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 77 (rMTB41 381-395)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LAARGTTGGGGTRSG</LinearSequence>
                                        <StartingPosition>381</StartingPosition>
                                        <EndingPosition>395</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12280</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 77 (rMTB41 381-395)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LAARGTTGGGGTRSG</LinearSequence>
                                        <StartingPosition>381</StartingPosition>
                                        <EndingPosition>395</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 78 (rMTB41 386-400)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TTGGGGTRSGTSTDG</LinearSequence>
                        <StartingPosition>386</StartingPosition>
                        <EndingPosition>400</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>66622</EpitopeId>
                <ReferenceStartingPosition>386</ReferenceStartingPosition>
                <ReferenceEndingPosition>400</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12282</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 78 (rMTB41 386-400)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TTGGGGTRSGTSTDG</LinearSequence>
                                        <StartingPosition>386</StartingPosition>
                                        <EndingPosition>400</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12281</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 78 (rMTB41 386-400)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TTGGGGTRSGTSTDG</LinearSequence>
                                        <StartingPosition>386</StartingPosition>
                                        <EndingPosition>400</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 79 (rMTB41 391-405)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GTRSGTSTDGQEDGR</LinearSequence>
                        <StartingPosition>391</StartingPosition>
                        <EndingPosition>405</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>22804</EpitopeId>
                <ReferenceStartingPosition>391</ReferenceStartingPosition>
                <ReferenceEndingPosition>405</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12284</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 79 (rMTB41 391-405)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GTRSGTSTDGQEDGR</LinearSequence>
                                        <StartingPosition>391</StartingPosition>
                                        <EndingPosition>405</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12283</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 79 (rMTB41 391-405)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GTRSGTSTDGQEDGR</LinearSequence>
                                        <StartingPosition>391</StartingPosition>
                                        <EndingPosition>405</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 80 (rMTB41 396-410)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TSTDGQEDGRKPPVV</LinearSequence>
                        <StartingPosition>396</StartingPosition>
                        <EndingPosition>410</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>66453</EpitopeId>
                <ReferenceStartingPosition>396</ReferenceStartingPosition>
                <ReferenceEndingPosition>410</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12285</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 80 (rMTB41 396-410)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TSTDGQEDGRKPPVV</LinearSequence>
                                        <StartingPosition>396</StartingPosition>
                                        <EndingPosition>410</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12286</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 80 (rMTB41 396-410)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TSTDGQEDGRKPPVV</LinearSequence>
                                        <StartingPosition>396</StartingPosition>
                                        <EndingPosition>410</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 81 (rMTB41 401-415)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>QEDGRKPPVVVIREQ</LinearSequence>
                        <StartingPosition>401</StartingPosition>
                        <EndingPosition>415</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>50565</EpitopeId>
                <ReferenceStartingPosition>401</ReferenceStartingPosition>
                <ReferenceEndingPosition>415</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12288</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 81 (rMTB41 401-415)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QEDGRKPPVVVIREQ</LinearSequence>
                                        <StartingPosition>401</StartingPosition>
                                        <EndingPosition>415</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12287</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 81 (rMTB41 401-415)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>QEDGRKPPVVVIREQ</LinearSequence>
                                        <StartingPosition>401</StartingPosition>
                                        <EndingPosition>415</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 82 (rMTB41 406-420)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KPPVVVIREQPPPGN</LinearSequence>
                        <StartingPosition>406</StartingPosition>
                        <EndingPosition>420</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>32842</EpitopeId>
                <ReferenceStartingPosition>406</ReferenceStartingPosition>
                <ReferenceEndingPosition>420</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12289</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 82 (rMTB41 406-420)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KPPVVVIREQPPPGN</LinearSequence>
                                        <StartingPosition>406</StartingPosition>
                                        <EndingPosition>420</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12290</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 82 (rMTB41 406-420)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KPPVVVIREQPPPGN</LinearSequence>
                                        <StartingPosition>406</StartingPosition>
                                        <EndingPosition>420</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Peptide 83 (rMTB41 411-423)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>VIREQPPPGNPPR</LinearSequence>
                        <StartingPosition>411</StartingPosition>
                        <EndingPosition>423</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q79FV1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>83332</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>69098</EpitopeId>
                <ReferenceStartingPosition>411</ReferenceStartingPosition>
                <ReferenceEndingPosition>423</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The antigen was named as MTB41 by the authors. More information about this antigen can be found in the TubercuList H37Rv database (Rv0915c).</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12292</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>Q79FV1.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Recombinant MTB1 protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Adjuvant>ASO2A</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>three times, 1 month apart</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 83 (rMTB41 411-423)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VIREQPPPGNPPR</LinearSequence>
                                        <StartingPosition>411</StartingPosition>
                                        <EndingPosition>423</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>12291</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>83332</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M.tuberculosis H37Rv</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intravenous (i.v.)</Route>
                                <DoseSchedule>one</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were infected with 10&lt;sup&gt;5&lt;/sup&gt; CFU of M.tuberculosis H37Rv.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Lymphocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>Peptide 83 (rMTB41 411-423)</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>VIREQPPPGNPPR</LinearSequence>
                                        <StartingPosition>411</StartingPosition>
                                        <EndingPosition>423</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q79FV1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>83332</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Except for peptide 1 (MDFGLLPPEVNSSRM) all other 15-mer overlapping peptides in rMTb41 antigen stimulated the formation of &lt;2 spots / culture. Mice were either infected intravenously with M.tuberculosis or were immunized intravenously with rMTB41 mixed with the adjuvant ASO2A. Lymphoid cells obtained from spleens of infected mice were cultured for 3 days with peptide.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

